Very happy to say that we have more good news to share. The final efficacy analysis of @Pfizer's Phase 3 study showed that our #COVID19 vaccine candidate met all of the study's primary efficacy endpoints: pfizer.com/news/press-rel…
Most notably, the vaccine candidate was shown to be 95% effective in helping prevent #COVID19 beginning 28 days after the first dose.
We also announced that the safety database required by the @US_FDA for Emergency Use Authorization (EUA) has been achieved.
As a result, we plan to submit a request within days to the @US_FDA for an EUA based on the safety & efficacy data collected to date, as well as manufacturing data relating to the vaccine candidate. These data will also be submitted to other regulatory agencies around the world.
We continue to move at the speed of science, and we know that every day matters in our path to authorization. My thanks to everyone working day and night to help us make this a reality. #ScienceWillWin
• • •
Missing some Tweet in this thread? You can try to
force a refresh
